TerminatedNot Applicable

Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis

Stopped: Lack of recruitment

Belgium28 participantsStarted 2023-10-20

Plain-language summary

This exploratory study aims to evaluate the effects of the test product RV5026B - ET1732 on erythema, as well as on the sensations of discomfort and relief perceived in subjects with erythrocouperose and associated pityriasis folliculorum. We wish to evaluate: * firstly the test product alone in order to quantify the effects on the signs \& symptoms on the entire face, * then the contribution of the test product in addition to a reference topical treatment. The test product RV5026B - ET1732 was developed to: * Reduce redness, even if it has already set in, and help limit its reappearance * Soothe the sensations of heating and discomfort associated

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. ORAL/GENERAL TREATMENTS that were planned to be taken during the study OR that were taken:
. LOCAL TREATMENTS that were planned to be taken during the study OR that were taken:

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Erythema score

Timeframe: Day 1, Day 29 & Day 57

Overall dynamic efficiency score

Timeframe: Day 29 & Day 57

Demodex density

Timeframe: Day 1, Day 29 & Day 57

Rating of the intensity of the erythema

Timeframe: Day 1, Day 29 & Day 57

Flush score

Timeframe: Day 1, Day 29 & Day 57

Dynamic SGA (subject global assessment) scale

Timeframe: Day 1, Day 29 & Day 57

Subject acceptability questionnaire

Timeframe: Day 29 & Day 57

Tolerance of the products for 2 months of use by adverse events

Trial details

NCT IDNCT06824870

SponsorPierre Fabre Dermo Cosmetique

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-02-20

View on ClinicalTrials.gov More Erythrocouperose Associated With Pityriasis Folliculorum of the Face trials

Plain-language summary

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. ORAL/GENERAL TREATMENTS that were planned to be taken during the study OR that were taken:
. LOCAL TREATMENTS that were planned to be taken during the study OR that were taken:

What they're measuring

Erythema score

Timeframe: Day 1, Day 29 & Day 57

Overall dynamic efficiency score

Timeframe: Day 29 & Day 57

Demodex density

Timeframe: Day 1, Day 29 & Day 57

Rating of the intensity of the erythema

Timeframe: Day 1, Day 29 & Day 57

Flush score

Timeframe: Day 1, Day 29 & Day 57

Dynamic SGA (subject global assessment) scale

Timeframe: Day 1, Day 29 & Day 57

Subject acceptability questionnaire

Timeframe: Day 29 & Day 57

Tolerance of the products for 2 months of use by adverse events